Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 3/20 | 0.54 |
| ▸ | NPC1 | O15118 | 2/20 | 0.54 |
| ▸ | GAA | P10253 | 2/20 | 0.53 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | THRB | P10828 | 1/20 | 0.50 |
| ▸ | BLM | P54132 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Piperazine SCHEMBL28890005 | 0.90 | RAB9A (0.47) | HSD17B10RAB9ANPC1GAATAAR1 | |
| SCHEMBL5702341 | 0.89 | RAB9A (0.62) | RAB9ANPC1GAATAAR1KMT2A | |
| SCHEMBL27964104 | 0.85 | RAB9A (0.49) | RAB9ANPC1GAATAAR1MAPT | |
| SCHEMBL1895641 | 0.85 | TAAR1 (0.58) | RAB9ANPC1GAATAAR1 | |
| SCHEMBL10812056 | 0.84 | KMT2A (0.63) | RAB9ANPC1GAAMAPTKMT2A | |
| SCHEMBL13055389 | 0.83 | TAAR1 (0.60) | HSD17B10RAB9ANPC1GAATAAR1 | |
| SCHEMBL9778357 | 0.83 | HSD17B10 (0.57) | HSD17B10RAB9ANPC1GAATAAR1 | |
| SCHEMBL6230420 | 0.83 | L3MBTL1 (0.54) | RAB9ANPC1GAAMAPTKMT2A | |
| SCHEMBL13911210 | 0.82 | GAA (0.59) | RAB9ANPC1GAATAAR1ALDH1A1 | |
| SCHEMBL2453184 | 0.82 | KMT2A (0.54) | RAB9ANPC1GAATAAR1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 194 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113024418-B | Method for synthesizing alicyclic carbamate by using isopropanol as hydrogen source | 河北工业大学 | 2023-01-24 | — | — | CN | claimed |
| CN-113926403-A | Preparation device and method of diphenylmethane dicarbamic acid ester | 中国科学院过程工程研究所 | 2022-01-14 | — | — | CN | claimed |
| CN-112898184-A | Method for continuously synthesizing alicyclic carbamate | 河北工业大学 | 2021-06-04 | — | — | CN | claimed |
| EP-1663994-B1 | TETRAHYDROQUINAZOLINE COMPOUNDS AS INHIBITORS OF VOLTAGE-GATED ION CHANNELS | VERTEX PHARMA (US) | 2012-03-07 | — | — | EP | claimed |
| JP-4808156-B2 | — | — | 2011-11-02 | — | — | JP | claimed |
| CN-100491368-C | Dioxane-2-alkyl carbamate derivatives | SANOFI AVENTIS (FR) | 2009-05-27 | — | — | CN | claimed |
| CN-101356173-A | Novel pyridopyrazines and their use as modulators of kinases | AETERNA ZENTARIS GMBH (DE) | 2009-01-28 | — | — | CN | claimed |
| US-20070149484-A1 | NOVEL PYRIDOPYRAZINES AND THEIR USE AS MODULATORS OF KINASES | ZENTARIS GMBH (DE) | 2007-06-28 | — | — | US | claimed |
| CN-1898201-A | Carbamoyl esters that inhibit cholinesterase and release pharmacologically active agents | SENTION INC (US) | 2007-01-17 | — | — | CN | claimed |
| EP-1663994-A1 | CONDENSED PYRIMIDINE COMPOUNDS AS INHIBITORS OF VOLTAGE-GATED ION CHANNELS | Vertex Pharmaceuticals Incorporated (US) | 2006-06-07 | — | — | EP | claimed |
| CN-1777595-A | Dioxane-2-alkylcarbamate derivatives, their preparation and their therapeutic use | SANOFI AVENTIS (FR) | 2006-05-24 | — | — | CN | claimed |
| US-20050187217-A1 | Compositions useful as inhibitors of voltage-gated ion channels | VERTEX PHARMACEUTICALS INCORPORATED | 2005-08-25 | — | — | US | claimed |
| EP-1517708-A1 | COMBINATION TREATMENT FOR DEPRESSION AND ANXIETY BY NK1 AND NK3 ANTAGONISTS | Pfizer Products Inc. (US) | 2005-03-30 | — | — | EP | claimed |
| WO-2005014558-A1 | CONDENSED PYRAMIDINE COMPOUNDS AS INHIBITORS OF VOLTAGE-GATED ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2005-02-17 | — | — | WO | claimed |
| WO-2004000355-A1 | COMBINATION TREATMENT FOR DEPRESSION AND ANXIETY BY NK1 AND NK3 ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 2003-12-31 | — | — | WO | claimed |
| EP-4004001-B1 | SUBSTITUTED PYRIMIDINEDIONE COMPOUNDS AND USES THEREOF | SUNSHINE LAKE PHARMA CO LTD (CN) | 2025-09-03 | — | — | EP | disclosed |
| CN-119019380-A | Benzimidazole-6-sulfonylurea compound and medical application thereof | 南京羚诺生物医药技术研究院有限公司 | 2024-11-26 | — | — | CN | disclosed |
| US-4162362-A | CONDESATION OF N-ARYL CARBAMIC ACID ESTER WITH FORMALDEHYDE IN THE PRESENCE OF A SULFONIC ACID | ATLANTIC RICHFIELD COMPANY (US) | 1979-07-24 | — | — | US | disclosed |
| US-4123450-A | Process for preparing alkyl isocyanates | FMC CORPORATION (US) | 1978-10-31 | — | — | US | disclosed |
| US-3938986-A | ISOPROPYL N-PHENYLCARBAMATE OR ISOPROPYL N-(3-CHLOROPHENYL)CARBAMATE AND 4-CHLOROPHENYL N-METHYLCARBAMATE | PPG INDUSTRIES, INC. (US) | 1976-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050187217-A1 | Compositions useful as inhibitors of voltage-gated ion channels | KCNQ1, KCNN2, KCNH3 | HSD17B10 2449/4885RAB9A 1702/4885NPC1 493/4885 |
| US-20070149484-A1 | NOVEL PYRIDOPYRAZINES AND THEIR USE AS MODULATORS OF KINASES | MAP4K2, MAP3K15, MAP3K5 | HSD17B10 4090/4885RAB9A 3378/4885NPC1 4680/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.